A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver
Ontology highlight
ABSTRACT: Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a 1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan. Postoperatively, patients will be treated with hepatic arterial infusion of floxuridine (FUDR), 0.2 mg/kg/day and leucovorin (LV), 15 mg/M2/day as a 2-week continuous infusion regimen. Hepatic and systemic toxicity, response to treatment, duration of response, and survival will be followed.
DISEASE(S): Neoplasm Metastasis,Colorectal Neoplasm,Colorectal Neoplasms,Liver Neoplasms,Liver Neoplasm,Neoplasms
PROVIDER: 2001372 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA